Paediatric septic arthritis in a tertiary setting: a retrospective analysis

dc.contributor.authorVisser, Hilgaard Frans
dc.contributor.authorVisser, Adele
dc.contributor.authorGoller, K.
dc.contributor.authorGoller, Ruan
dc.contributor.authorNel, J.M.
dc.contributor.authorSnyckers, Christian Hugo
dc.contributor.emailadele@up.ac.zaen_US
dc.date.accessioned2010-10-27T14:03:09Z
dc.date.available2010-10-27T14:03:09Z
dc.date.issued2010
dc.description.abstractPURPOSE OF THE STUDY: Acute haematogenous septic arthritis is a relatively common condition in the paediatric population. Although Staphylococcus aureus is implicated as the most common causative agent, changes in resistance and the increasing importance of other pathogens have been reported. The purpose of this study is to establish the spectrum of aetiological organisms with their respective sensitivities, and to use this data to evaluate choices in empiric antimicrobial therapy. DESCRIPTION OF METHODS: A retrospective analysis was performed on patients aged 12 years and younger, admitted for suspected septic arthritis, at a tertiary hospital in South Africa from June 2005 to March 2009. All patients with a clinical diagnosis of septic arthritis were included in this study. SUMMARY OF RESULTS: A total of 44 patients from the age of 2 weeks to 12 years were included. Thirty-nine samples were submitted for microbiological investigation. Thirty of these samples yielded bacterial growth; five of these had two microorganisms. Gram-positive organisms were cultured in 79% of isolates. Staphylococcus aureus was cultured in 66% of all isolates. Only three samples were multi-drug resistant. Gram-negative organisms constituted 17% of isolates. Of note is the isolation of a single isolate of Haemophilus influenzae type B, signifying possible vaccine or vaccination failure. CONCLUSION: Gram-positive organisms, in particular Staphylococcus aureus, are still the most prevalent aetiological agent. The current use of cloxacillin as empiric antibiotic therapy will cover 69% of all isolates in this setting; use of coamoxyclav as empiric therapy will increase cover to 80%. Although this 11% difference is seemingly small, opting for co-amoxyclav may significantly reduce morbidity.en_US
dc.identifier.citationVisser, HF, Visser, A, Goller, K, Goller, R, Nel, JM & Snyckers, CH 2010, 'Paediatric septic arthritis in a tertiary setting: a retrospective analysis', SA Orthopaedic Journal, vol. 9, no. 2, pp. 92-96. [http://www.charpublications.co.za/C_JournalsORTH.asp]en_US
dc.identifier.issn1681-150X
dc.identifier.urihttp://hdl.handle.net/2263/15101
dc.language.isoenen_US
dc.publisherSouth African Orthopaedic Association / Char Publicationsen_US
dc.rightsSouth African Orthopaedic Association / Char Publicationsen_US
dc.subjectSeptic arthritisen_US
dc.subjectPaediatricsen_US
dc.subjectEtiologyen_US
dc.titlePaediatric septic arthritis in a tertiary setting: a retrospective analysisen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Visser_Paediatric(2010).pdf
Size:
445.77 KB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.44 KB
Format:
Item-specific license agreed upon to submission
Description: